Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Emerg Infect Dis ; 29(5): 992-996, 2023 05.
Article in English | MEDLINE | ID: mdl-36821867

ABSTRACT

Heartland virus (HRTV) disease is an emerging tickborne illness in the midwestern and southern United States. We describe a reported fatal case of HRTV infection in the Maryland and Virginia region, states not widely recognized to have human HRTV disease cases. The range of HRTV could be expanding in the United States.


Subject(s)
Bunyaviridae Infections , Phlebovirus , Virus Diseases , United States/epidemiology , Humans , Bunyaviridae Infections/diagnosis , Phlebovirus/genetics , Mid-Atlantic Region
2.
Zoonoses Public Health ; 67(6): 637-650, 2020 09.
Article in English | MEDLINE | ID: mdl-32638553

ABSTRACT

Established populations of Asian longhorned ticks (ALT), Haemaphysalis longicornis, were first identified in the United States (US) in 2017 by sequencing the mitochondrial cytochrome c oxidase subunit I (cox1) 'barcoding' locus followed by morphological confirmation. Subsequent investigations detected ALT infestations in 12, mostly eastern, US states. To gain information on the origin and spread of US ALT, we (1) sequenced cox1 from ALT populations across 9 US states and (2) obtained cox1 sequences from potential source populations [China, Japan and Republic of Korea (ROK) as well as Australia, New Zealand and the Kingdom of Tonga (KOT)] both by sequencing and by downloading publicly available sequences in NCBI GenBank. Additionally, we conducted epidemiological investigations of properties near its initial detection locale in Hunterdon County, NJ, as well as a broader risk analysis for importation of ectoparasites into the area. In eastern Asian populations (China/Japan/ROK), we detected 35 cox1 haplotypes that neatly clustered into two clades with known bisexual versus parthenogenetic phenotypes. In Australia/New Zealand/KOT, we detected 10 cox1 haplotypes all falling within the parthenogenetic cluster. In the United States, we detected three differentially distributed cox1 haplotypes from the parthenogenetic cluster, supporting phenotypic evidence that US ALT are parthenogenetic. While none of the source populations examined had all three US cox1 haplotypes, a phylogeographic network analysis supports a northeast Asian source for the US populations. Within the United States, epidemiological investigations indicate ALT can be moved long distances by human transport of animals, such as horses and dogs, with smaller scale movements on wildlife. These results have relevant implications for efforts aimed at minimizing the spread of ALT in the United States and preventing additional exotic tick introductions.


Subject(s)
Animal Distribution , Ixodidae/physiology , Animals , DNA, Mitochondrial/genetics , Electron Transport Complex IV/genetics , Gene Expression Regulation, Enzymologic , United States
4.
Emerg Infect Dis ; 24(3): 553-557, 2018 03.
Article in English | MEDLINE | ID: mdl-29460762

ABSTRACT

We detected Cache Valley virus in Aedes japonicus, a widely distributed invasive mosquito species, in an Appalachian forest in the United States. The forest contained abundant white-tailed deer, a major host of the mosquito and virus. Vector competence trials indicated that Ae. j. japonicus mosquitoes can transmit this virus in this region.


Subject(s)
Aedes/virology , Bunyamwera virus , Bunyaviridae Infections/epidemiology , Bunyaviridae Infections/transmission , Animals , Appalachian Region/epidemiology , Bunyamwera virus/classification , Bunyamwera virus/genetics , Bunyaviridae Infections/virology , Geography , Humans , Public Health Surveillance
5.
J Bone Joint Surg Am ; 96(23): 1990-8, 2014 Dec 03.
Article in English | MEDLINE | ID: mdl-25471914

ABSTRACT

BACKGROUND: Lithium, a treatment for bipolar disorder, is not clinically indicated for use in fracture management but has been reported to positively influence bone biology. It is hypothesized that lithium dosing for beneficial effects on bone health may be much lower than the dosing required for psychotropic benefits in patients with bipolar disorder. A preclinical study with a rodent fracture model was utilized to best define the lowest effective dose, best timing of treatment onset, and optimal treatment duration for the use of lithium as a new treatment in fracture care. METHODS: A design-of-experiments approach was used to assess the parameters of dose, timing of treatment onset, and treatment duration. Closed femoral shaft fractures were generated and analyzed with use of destructive torsional mechanical testing and microcomputed tomography-based image analysis. Eleven different outcome measures were quantified, with maximum yield torque as the primary study outcome, to assess the quality of long-bone fracture-healing. RESULTS: Fracture-healing was maximized with a lithium treatment combination of a low dose (twenty milligrams per kilogram of body weight per day), later onset of lithium treatment (seven days after fracture), and longer treatment duration (two weeks), with maximum yield torque displaying a 46% increase compared with nontreated and sham-treated controls (481.1 ± 104.0 N-mm compared with 329.9 ± 135.8 N-mm; p = 0.04). Design-of-experiments analysis determined the timing of treatment onset to be the most influential parameter for improving fracture-healing, with femora treated at a later onset (seven days after fracture) showing a significant (21%) increase in maximum yield torque compared with those treated at an earlier onset (three days after fracture) (p = 0.01). CONCLUSIONS: A later onset of lithium administration significantly improved femoral fracture-healing. Trends indicated that a lower dose and longer treatment duration also had a positive effect on fracture repair. CLINICAL RELEVANCE: Orally administered low-dose lithium therapy with a large postfracture administration window has the potential to yield a safe, reliable, and cost-effective treatment to enhance bone-healing and restore earlier function and mobility pending appropriate large-animal proof-of-concept models, safety data, and U.S. Food and Drug Administration clinical trials approval.


Subject(s)
Femoral Fractures/drug therapy , Fracture Healing/drug effects , Fractures, Closed/drug therapy , Lithium/administration & dosage , Protein Kinase Inhibitors/administration & dosage , Administration, Oral , Animals , Biomechanical Phenomena , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Femoral Fractures/physiopathology , Fractures, Closed/physiopathology , Lithium/pharmacology , Lithium/therapeutic use , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Rats , Rats, Sprague-Dawley , Torque , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...